Index - P/E - EPS (ttm) - Insider Own 46.38% Shs Outstand 22.24M Perf Week -25.02%
Market Cap 201.27M Forward P/E - EPS next Y -3.83 Insider Trans 9.70% Shs Float 11.93M Perf Month -32.71%
Income - PEG - EPS next Q -0.64 Inst Own 12.31% Short Float 4.31% Perf Quarter -
Sales - P/S - EPS this Y 92.13% Inst Trans - Short Ratio 1.98 Perf Half Y -
Book/sh -5.71 P/B - EPS next Y -19.84% ROA - Short Interest 0.51M Perf Year -
Cash/sh 5.43 P/C 1.67 EPS next 5Y 13.20% ROE - 52W Range 8.97 - 15.24 Perf YTD -36.49%
Dividend Est. - P/FCF - EPS past 5Y - ROI - 52W High -40.62% Beta -
Dividend TTM - Quick Ratio 13.27 Sales past 5Y 0.00% Gross Margin - 52W Low 0.91% ATR (14) 1.17
Dividend Ex-Date - Current Ratio 13.27 EPS Y/Y TTM - Oper. Margin - RSI (14) - Volatility 14.88% 10.10%
Employees 72 Debt/Eq - Sales Y/Y TTM - Profit Margin - Recom 1.00 Target Price 23.00
Option/Short No / Yes LT Debt/Eq - EPS Q/Q - Payout - Rel Volume 0.58 Prev Close 10.00
Sales Surprise - EPS Surprise - Sales Q/Q - Earnings - Avg Volume 258.80K Price 9.05
SMA20 -20.01% SMA50 -22.74% SMA200 -22.74% Trades
Volume 149,930 Change -9.50%
Date
Action
Analyst
Rating Change
Price Target Change
Apr-22-24 Initiated Piper Sandler
Overweight
$20
Apr-22-24 Initiated Leerink Partners
Outperform
$25
Apr-22-24 Initiated Guggenheim
Buy
$24
May-01-24 10:05AM
Apr-14-24 11:37AM
Apr-11-24 08:00AM
Apr-08-24 08:00AM
Mar-27-24 06:55PM
Boundless Bio, Inc. is a clinical-stage oncology company, which is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA. The company was founded by Vineet Bafna, Paul Mischel, Benjamin F. Cravatt, and Jonathan E. Lim on April 10, 2018 and is headquartered in San Diego, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
RA CAPITAL MANAGEMENT, L.P. 10% Owner Apr 02 '24 Buy 16.00 312,500 5,000,000 1,884,787 Apr 04 04:15 PM ARCH Venture Fund IX, L.P. 10% Owner Apr 02 '24 Buy 16.00 200,000 3,200,000 1,181,766 Apr 04 04:30 PM CRANDELL KEITH 10% Owner Apr 02 '24 Buy 16.00 200,000 3,200,000 1,181,766 Apr 04 04:30 PM Burow Kristina Director Apr 02 '24 Buy 16.00 200,000 3,200,000 1,181,766 Apr 04 04:30 PM
Index RUT P/E - EPS (ttm) -1.46 Insider Own 44.41% Shs Outstand 197.86M Perf Week 15.06%
Market Cap 2.16B Forward P/E - EPS next Y -1.30 Insider Trans 5.76% Shs Float 123.02M Perf Month 6.77%
Income -283.25M PEG - EPS next Q -0.30 Inst Own 40.53% Short Float 21.72% Perf Quarter 67.75%
Sales 0.00M P/S - EPS this Y 19.23% Inst Trans 1.62% Short Ratio 13.04 Perf Half Y 230.41%
Book/sh 1.45 P/B 6.73 EPS next Y -9.95% ROA -40.81% Short Interest 26.72M Perf Year 93.66%
Cash/sh 0.94 P/C 10.36 EPS next 5Y - ROE -72.00% 52W Range 2.74 - 12.00 Perf YTD 139.71%
Dividend Est. - P/FCF - EPS past 5Y -83.13% ROI -74.85% 52W High -18.50% Beta 1.61
Dividend TTM - Quick Ratio 3.31 Sales past 5Y 0.00% Gross Margin - 52W Low 256.28% ATR (14) 0.61
Dividend Ex-Date - Current Ratio 3.31 EPS Y/Y TTM -2.50% Oper. Margin 0.00% RSI (14) 61.76 Volatility 7.11% 6.72%
Employees 328 Debt/Eq 0.36 Sales Y/Y TTM - Profit Margin - Recom 1.67 Target Price 12.20
Option/Short Yes / Yes LT Debt/Eq 0.32 EPS Q/Q -5.73% Payout - Rel Volume 0.73 Prev Close 9.63
Sales Surprise - EPS Surprise -17.10% Sales Q/Q - Earnings Feb 29 AMC Avg Volume 2.05M Price 9.78
SMA20 12.83% SMA50 7.67% SMA200 67.35% Trades
Volume 1,494,339 Change 1.56%
Date
Action
Analyst
Rating Change
Price Target Change
Jan-16-24 Upgrade H.C. Wainwright
Neutral → Buy
$12
Sep-25-23 Initiated JMP Securities
Mkt Outperform
$9
Sep-05-23 Initiated Citigroup
Buy
$8
Aug-14-23 Initiated TD Cowen
Market Perform
May-02-23 Initiated H.C. Wainwright
Neutral
Mar-01-21 Initiated Morgan Stanley
Overweight
$40
Mar-01-21 Initiated JP Morgan
Neutral
$35
Mar-01-21 Initiated Goldman
Neutral
$40
Mar-01-21 Initiated BofA Securities
Buy
$45
Apr-08-24 08:00AM
Mar-19-24 10:00AM
08:30AM
Mar-11-24 07:00PM
Mar-07-24 09:01AM
04:55PM
Loading…
Feb-29-24 04:55PM
(Associated Press Finance) -5.90%
04:05PM
03:02AM
Feb-28-24 04:05PM
Feb-13-24 04:05PM
Feb-12-24 04:05PM
Feb-08-24 01:22AM
Feb-07-24 04:01PM
Jan-27-24 11:02AM
Jan-18-24 12:00PM
10:24AM
Loading…
10:24AM
Jan-09-24 08:44AM
Jan-08-24 06:30AM
06:30AM
Jan-05-24 09:00AM
Jan-03-24 04:05PM
Dec-19-23 09:01AM
Dec-11-23 09:00AM
Dec-01-23 04:05PM
Nov-27-23 07:01PM
Nov-21-23 09:00AM
06:00AM
Nov-17-23 09:00AM
Nov-09-23 04:05PM
Nov-08-23 04:05PM
09:05AM
Loading…
Nov-02-23 09:05AM
Nov-01-23 10:30AM
Oct-19-23 10:30AM
Oct-10-23 04:15PM
Oct-02-23 07:00AM
Sep-27-23 08:31AM
Sep-11-23 06:30AM
Aug-30-23 04:05PM
Aug-29-23 09:00AM
Aug-03-23 05:03PM
(Associated Press Finance)
04:05PM
Jun-16-23 09:00AM
May-31-23 04:05PM
May-22-23 07:33AM
May-16-23 06:00AM
May-08-23 04:35PM
04:26PM
04:05PM
May-04-23 01:56PM
May-03-23 04:05PM
09:55AM
May-02-23 04:30PM
12:50PM
Apr-24-23 04:05PM
Apr-20-23 10:07AM
Apr-19-23 04:05PM
Apr-17-23 09:55AM
06:17AM
Apr-14-23 10:27AM
Apr-13-23 09:00AM
Apr-12-23 04:05PM
Apr-10-23 04:05PM
Mar-24-23 03:20PM
Mar-16-23 04:05PM
Mar-14-23 04:53PM
Mar-01-23 04:05PM
Feb-10-23 08:18AM
Feb-02-23 04:05PM
Jan-26-23 04:05PM
Jan-03-23 04:05PM
Dec-11-22 05:30PM
Dec-01-22 12:11AM
(American City Business Journals) -11.22%
Nov-30-22 10:55AM
(American City Business Journals) +5.94%
08:43AM
Nov-29-22 04:05PM
Nov-17-22 01:58PM
Nov-14-22 04:05PM
Nov-03-22 09:07AM
Nov-02-22 04:05PM
Oct-18-22 07:43AM
Sep-09-22 04:05PM
Sep-03-22 08:39AM
Aug-09-22 11:54AM
Aug-04-22 04:05PM
Jun-17-22 09:00AM
Jun-13-22 04:05PM
Jun-07-22 04:05PM
Jun-02-22 01:55AM
(American City Business Journals) +9.26%
Jun-01-22 04:05PM
May-12-22 05:40PM
May-11-22 07:19AM
(Simply Wall St.) -13.46%
May-10-22 04:05PM
May-04-22 04:05PM
May-02-22 04:35PM
Mar-24-22 04:12PM
Mar-20-22 08:02AM
Mar-16-22 08:30AM
Mar-09-22 04:05PM
Mar-08-22 04:35PM
Feb-28-22 09:00AM
Sana Biotechnology, Inc. engages in the research and development of engineered cells as medicine. It focuses on identifying and developing potential product candidates, executing preclinical studies, and acquiring technology. The company was founded by Steven D. Harr, Noubar B. Afeyan, Robert Taylor Nelsen, and Hans Edgar Bishop on July 2018 and is headquartered in Seattle, WA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Yang Patrick Y Director Mar 08 '24 Sale 9.45 25,000 236,300 149,250 Mar 11 04:57 PM NELSEN ROBERT Director Feb 08 '24 Buy 5.50 1,818,181 9,999,996 12,446,022 Feb 12 05:46 PM ARCH Venture Fund X, L.P. 10% Owner Feb 08 '24 Buy 5.50 1,818,181 9,999,996 12,446,022 Feb 12 05:43 PM CRANDELL KEITH 10% Owner Feb 08 '24 Buy 5.50 1,818,181 9,999,996 12,446,022 Feb 12 05:43 PM Hordo Christian EVP, Chief Business Officer Dec 15 '23 Sale 4.00 75,000 300,098 867,455 Dec 18 04:51 PM Flagship Ventures Fund V Gener 10% Owner Jun 07 '23 Sale 6.24 200,000 1,247,940 1,380,277 Jun 08 07:00 PM Flagship Ventures Fund V Gener 10% Owner Jun 06 '23 Sale 6.31 203,758 1,284,918 1,403,037 Jun 08 07:00 PM Flagship Ventures Fund V Gener 10% Owner May 26 '23 Sale 6.23 82,000 510,573 1,425,334 May 26 08:00 PM Flagship Ventures Fund V Gener 10% Owner May 25 '23 Sale 6.35 115,372 732,866 1,434,664 May 26 08:00 PM Flagship Ventures Fund V Gener 10% Owner May 24 '23 Sale 6.57 347,870 2,283,836 1,447,791 May 26 08:00 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite
